The new issue of Oxurion Perspectives magazine is here. Read about last year's highlights and the ambitious times ahead.
Patrik De Haes, M.D., CEO of Oxurion, and Thomas Clay, Chairman of the Board, review the year 2019.
“As an investigator of THR-149, I was encouraged to see the results from its clinical phase 1 trial", Pravin Dugel, M.D., says.
In 2019, Oxurion announced positive topline data for the compound THR-149, a highly potent plasma kallikrein inhibitor to treat diabetic macular edema (DME).
Jean Feyen, PhD., Chief Scientific Officer, and Andy De Deene, M.D., Global Head of Development, explain why Oxurion decided to focus on non-VEGF pathways.
“The new name comes from combining the words Oxygen and Orion”, explains CEO Patrik De Haes, MD. “Raising oxygen levels in cells plays a key role in helping prevent and reverse ...